Analysts Set Revvity Inc. (NYSE:RVTY) Price Target at $120.07

Key Points

• Revvity Inc. has received a consensus rating of "Moderate Buy" from fourteen analysts, with ten analysts recommending buying the stock and four advising to hold it.
• The average twelve-month price target for Revvity is $120.07, though some analysts have adjusted their targets down recently, with Stifel Nicolaus setting it at $110.00.
• Revvity has declared a quarterly dividend of $0.07 per share, which is expected to be paid on November 7, indicating a relatively low payout ratio of 11.86%.

Shares of Revvity Inc. (NYSE:RVTY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $120.0714.

A number of research analysts have recently commented on the company. Raymond James Financial restated an "outperform" rating and issued a $115.00 target price (down previously from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Evercore ISI lowered their target price on Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Bank of America lowered their target price on Revvity from $116.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Stifel Nicolaus lowered their target price on Revvity from $120.00 to $110.00 and set a "hold" rating for the company in a research note on Tuesday, July 29th. Finally, Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RVTY. Price T Rowe Associates Inc. MD lifted its stake in shares of Revvity by 25.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company's stock valued at $1,011,863,000 after purchasing an additional 1,932,314 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Revvity by 8.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company's stock valued at $2,382,163,000 after buying an additional 1,754,403 shares in the last quarter. EdgePoint Investment Group Inc. increased its position in Revvity by 26.7% during the 2nd quarter. EdgePoint Investment Group Inc. now owns 6,789,660 shares of the company's stock valued at $656,696,000 after buying an additional 1,428,813 shares in the last quarter. Norges Bank bought a new position in Revvity during the 2nd quarter valued at approximately $124,574,000. Finally, Invesco Ltd. increased its position in Revvity by 25.8% during the 2nd quarter. Invesco Ltd. now owns 2,207,202 shares of the company's stock valued at $213,481,000 after buying an additional 452,343 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Trading Down 2.6%

NYSE RVTY traded down $2.37 on Thursday, hitting $87.74. The company's stock had a trading volume of 1,302,553 shares, compared to its average volume of 1,045,733. Revvity has a 52-week low of $85.12 and a 52-week high of $129.50. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. The company's 50-day simple moving average is $93.84 and its 200 day simple moving average is $97.69. The firm has a market cap of $10.18 billion, a P/E ratio of 37.18, a PEG ratio of 2.42 and a beta of 0.94.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The business had revenue of $720.28 million during the quarter, compared to analysts' expectations of $711.26 million. During the same quarter last year, the business posted $1.22 EPS. The business's revenue was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Research analysts predict that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity's dividend payout ratio (DPR) is presently 11.86%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.